Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 May 21;2(2):43-48.
doi: 10.14744/hf.2021.2021.0003. eCollection 2021 May.

Significance of detectable hepatitis B virus DNA in liver allograft tissue in long-term follow-up of liver transplant recipients

Deniz Mut Surmeli  1 , Ilker Turan  2 , Sinan Akay  3 , Selda Erensoy  4 , Galip Ersoz  2 , Fulya Gunsar  2 , Ulus Akarca  2 , Zeki Karasu  2
Affiliations

Significance of detectable hepatitis B virus DNA in liver allograft tissue in long-term follow-up of liver transplant recipients

Deniz Mut Surmeli et al. Hepatol Forum. .

Abstract

Background and aim: The objective of this study was to evaluate the long-term presence of hepatitis B virus (HBV) DNA in the liver grafts of liver transplant patients who received hepatitis B immunoglobulin (HBIg) plus oral antiviral hepatitis B virus prophylaxis and had negative HBV serum markers.

Materials and methods: Patients aged 18 years or older who underwent liver transplantation for HBV-related liver disease, had negative serum viral markers, and had a liver biopsy at least 3 years after liver transplantation were eligible for this study. Clinical, serological, and pathological data were retrospectively obtained from medical records. The HBV DNA of liver biopsy specimens was assessed using the polymerase chain reaction technique.

Results: A total of 150 patients were included. A positive HBV DNA result was seen in 18 (12%) of the liver biopsies. The presence of intrahepatic HBV DNA was not associated with pre-transplantation serum viral markers, type of pre- or post-transplantation antiviral treatment, or post-transplantation immunosuppressive treatment.

Conclusion: The findings suggest that while treatment with HBIg plus oral antiviral as post-transplantation HBV prophylaxis may result in a percentage of patients with persistent HBV DNA in the graft, the presence of HBV DNA in the liver graft may not be related to clinical HBV recurrence.

Keywords: Hepatitis B virus; liver failure; liver transplantation.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: The authors have no conflict of interest to declare.

Figures

Figure 1.
Figure 1.
Flowchart of the study population. HBsAg: Hepatitis B surface antigen; HBV: Hepatitis B virus.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. World Health Organization . Geneva: World Health Organization; 2017. Global Hepatitis Report 2017.
    1. McMillan JS, Shaw T, Angus PW, Locarnini SA. Effect of immunosuppressive and antiviral agents on hepatitis B virus replication in vitro. Hepatology. 1995;22(1):36–43. - PubMed
    1. Degos F, Lugassy C, Degott C, Debure A, Carnot F, Theirs V, et al. Hepatitis B virus and hepatitis B-related viral infection in renal transplant recipients. A prospective study of 90 patients. Gastroenterology. 1988;94:151–156. - PubMed
    1. Demetris AJ, Jaffe R, Sheahan DG, Burnham J, Spero J, Iwatsuki S, et al. Recurrent hepatitis B in liver allograft recipients. Differentiation between viral hepatitis B and rejection. Am J Pathol. 1986;125:161–172. - PMC - PubMed
    1. Perrillo RP, Gish R, Falck-Ytter YT. American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology. 2015;148(1):221–244. .e3. - PubMed

LinkOut - more resources